Get Live Data

The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. REDX.L Share Price
  4. REDX.L Share Regulatory News
  5. Redx Pharma

Pin to quick picksREDX.L Regulatory News (REDX)

REDX.L Information
  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Redx Pharma

9 Apr 2020 18:10

RNS Number : 4476J
FTSE Russell
09 April 2020
 

 

 

 

 

Redx Pharma (UK): Constituent DeletionChanges in FTSE UK Index Series

09 April 2020

Following the cash offer for Redx Pharma (UK, constituent) by RM Special Holdings LLC (non constituent) being declared unconditional in all respects, please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE AIM All-Share Index

16 April 2020

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSSSSFWUESSESL
12345678910
Date   Source Headline
31st Jul 20177:00 amRNSDisposal of BTK inhibitor drug development program
23rd Jun 20172:38 pmRNSMHRA approval of Clinical Trial Application
22nd Jun 20177:00 amRNSUpdate on Suspension of Trading
24th May 20176:35 pmRNSStatement re. Suspension
24th May 20174:35 pmRNSSuspension - Redx Pharma plc
17th May 20177:00 amRNSInterim results for six months ended 31 March 2017
15th May 20177:00 amRNSPreclinical efficacy data presented on RXC005
4th May 20177:00 amRNSNotice of Interim Results
20th Apr 201711:20 amRNSResult of AGM
20th Apr 20177:00 amRNSAppointment of Chairman
7th Apr 20173:56 pmRNSNotice of Annual General Meeting
3rd Apr 20177:15 amRNSHardman: CARB-X - new strategic collaboration
30th Mar 20174:03 pmRNSRedx Pharma awarded US$1 million grant by CARB-X
21st Mar 20179:05 amRNSFinal Results Year Ended 30 September 2016
7th Mar 20174:33 pmRNSHolding(s) in Company
3rd Mar 20172:35 pmRNSHolding(s) in Company
3rd Mar 20172:27 pmRNSHolding(s) in Company
3rd Mar 20172:17 pmRNSHolding(s) in Company
2nd Mar 20175:01 pmRNSHolding(s) in Company
2nd Mar 20177:50 amRNSRedx presentations at AACR 2017
28th Feb 201710:35 amRNSResult of General Meeting and Issue of Equity
27th Feb 20175:50 pmRNSResult of Open Offer
10th Feb 20171:00 pmRNSResult of Placing
9th Feb 20177:00 amRNSAccelerated Book Build
8th Feb 20176:30 pmRNSAccelerated Book Build
27th Jan 20177:00 amRNSGrowing opportunity for Porcupine inhibitors
6th Dec 20167:00 amRNSReversible BTK poster at ASH meeting
30th Nov 20167:00 amRNSRXC004 pre-clinical profile
16th Nov 20163:22 pmRNSHolding(s) in Company
4th Nov 20167:00 amRNSReversible BTK data at ASH meeting
20th Oct 20167:00 amRNSDevelopment candidate chosen for leukaemia program
11th Oct 20169:32 amRNSExercise of Options and Total Voting Rights
27th Sep 20167:00 amRNSDiscovery of breakthrough antibiotic compounds
23rd Sep 20164:07 pmRNSHolding(s) in Company
21st Sep 20168:50 amRNSHolding(s) in Company
19th Sep 20167:00 amRNSRe: Porcupine inhibitor and cancer immunotherapy
16th Sep 201611:31 amRNSHolding(s) in Company
14th Sep 201610:47 amRNSHolding(s) in Company
8th Sep 20167:00 amRNSBoard & Senior Management Changes
6th Sep 20167:00 amRNSSupply agreement for expected clinical trial
8th Aug 201610:55 amRNSHardman Research: Moving to clinic, rising value
17th Jun 201612:15 pmRNSRedx to present at ASM Microbe 2016 Conference
24th May 20167:00 amRNSProof of concept with key oncology lead
24th May 20167:00 amRNSHalf-year Report
19th May 20167:00 amRNSRe Review on Antimicrobial Resistance
9th May 20167:00 amRNSBoard Appointment
26th Apr 20163:37 pmRNSHolding(s) in Company
19th Apr 20164:52 pmRNSHolding(s) in Company
18th Apr 20167:00 amRNSHolding(s) in Company
15th Apr 20165:10 pmRNSHolding(s) in Company
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.